main content start
Glyxambi combines empagliflozin and linagliptin in a once-daily tablet to improve blood glucose levels. Glyxambi has been shown to reduce the risk of death from heart disease. It is approved for adults with type 2 diabetes.
- Glyxambi is approved for adults with type 2 diabetes. It is not for treating type 1 diabetes.
- For adults with type 2 diabetes and heart disease, empagliflozin (one of the medications in Glyxambi) is also used to lower the risk of death from heart attack, stroke, or heart failure.
- Glyxambi is a tablet taken once daily in the morning with or without food.
- Common side effects may include increased urinary frequency, urinary tract infections, cold-like symptoms, and upper respiratory tract infections.
Glyxambi Specs
Key specification
Generic Name
Empagliflozin and Linagliptin Empagliflozin and Metformin HCl (Synjardy XR)
Drug Class
SGLT-2 inhibitors
General Information
Product Name
Glyxambi
Product Type
Oral Medications
Brand
BOEHRINGER INGELHEIM
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
